Peri-Implantitis

PHILADELPHIA, April 23, 2024 /PRNewswire/ -- Every year, roughly 3 million Americans receive implants to replace lost teeth. While this technology has represented a leap of progress in dental care, over time, inflammation and gum disease ― nurtured by microbial biofilms, or plaque ― can affect the soft tissue and bone surrounding the implant and cause these tooth replacements to fail. An innovative new implant now on the horizon may one day address these issues, disrupting biofilms through its inherent antimicrobial and anti-inflammatory properties. The design of this next generation implant is the work of Dr. Geelsu Hwang at Penn Dental Medicine, who has a background in engineering that he brings to his research on biofilms and their role in oral health. "The lack of a good seal between the implant structure and the surrounding gum, compared to a natural tooth, means that the risk of disease around the implant is quite high," Hwang says. The new implant he and his collaborators are developing would interfere with biofilms and combat peri-implant infection in two ways: First, the crown, the artificial tooth atop the implant structure, will be suffused with nanoparticles made of a chemical compound that naturally wards off bacteria. Hwang and his team have been experimenting with the compound barium titanate (BTO). Second, the base of the crown will contain LEDs that deliver a regular dose of phototherapy to the surrounding gum tissue, giving off light at a wavelength that has antibacterial and anti-inflammatory properties. The LEDs will be powered by the piezoelectric material in the crown (like the BTO) that converts the motion of chewing or toothbrushing to electrical energy. Hwang notes that this platform could one day be integrated not only into dental implants, but into other applications, such as joint replacements, as well. In 2023, the National Institutes of Health awarded Hwang a five-year grant to further advance the implant development. The NIH funding will support tests of the new implant technology, using laboratory cultures of human gum tissue and, ultimately, test implants in mini pigs as preparation for human clinical trials. In related research, he is also studying a new piezoelectric dental composite material for fillings. The material would generate an enhanced electrical charge at the interface from the mechanical pressure of chewing, and this on its own would inhibit bacterial colonization of the composite surface. Contact: Beth Adams [email protected] SOURCE Penn Dental Medicine

SALT LAKE CITY--(BUSINESS WIRE)-- Spectrum Solutions®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™. As advances in science continue to focus on the mouth-body connection and its direct link to systemic disease, SimplyPERIO™ fills a testing void by delivering more intelligent health measures with real clinical relevance using 16 oral targets from a single patient sample. Gum disease, also called periodontal disease, is one of the most undiagnosed and untreated diseases, but has some of the highest negative impacts on many bodily systems and functions. In addition, gum disease decreases a person’s ability to fight infection and inflammation. SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal and viral targets all for one affordable cost. Understanding treatment success is often influenced by host immunity and host response, this unique, highly sensitive and highly specific saliva test offers Providers the real opportunity to elevate patient care with the most complete oral health picture. “We are using science to make saliva diagnostics simple for both Patients and Providers. SimplyPERIO™ testing is not only pain-free it takes less than 30 seconds for a patient to collect their own sample,” said Dr. David Vigerust, PhD, Chief Science Officer at Spectrum Solutions. “In addition, our CAP accredited laboratory delivers Providers the independent, 3rd party results necessary for intelligent, data-supported patient conversations about stopping and even reversing their disease and systemic risks.” In the U.S., numbers illustrate that 80% of individuals over 35 have a form of gum disease. Gingivitis, periodontitis and peri-implantitis are all forms of gum disease. These numbers demonstrate that for the vast majority, there may be dangerous and damaging periodontal disease pathogens hiding that can't be identified with a perio-probe or visual exam during regular semi-annual cleanings. Gone unchecked, these harmful oral bacteria and toxins are allowed to sit and accumulate inside the mouth. From inside the mouth these microorganisms move freely to and through the bloodstream with far reaching and catastrophic effects on the heart, arteries, central nervous system and more. The SimplyPERIO™ patented blue buffer solution located inside the collection device’s cap stabilizes saliva samples at room temperature eliminating any special post-collection storage or shipping requirements. Easily deposit one at a time, supporting at-home patient testing for follow-up and treatment monitoring, or gather an entire day’s worth of in-office collections into the USPS postage-paid return box for mailing samples back to the lab for processing. ABOUT SPECTRUM SOLUTIONS® Headquartered in Salt Lake City, Utah, Spectrum Solutions is dedicated to empowering complete wellness and bridging the gap between science and innovative healthcare solutions. Our stand-alone and fully integrated test-to-treat solutions support molecular diagnostics and DTC testing applications, advancing product development and accelerating go-to-market applications. Our single-source, end-to-end capabilities include a CAP accredited molecular diagnostic laboratory, onsite compounding pharmacy, product development, manufacturing and fulfillment. SimplyTest® and Spectrum Solutions® are registered trademarks of Spectrum Solution, LLC. For more information, please visit spectrumsolution.com or simplytest.com.

New Episodes Will Feature Engaging Stories from Clinicians About the Benefits of Laser Technology in Dentistry LAKE FOREST, Calif., March 6, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced plans to launch a second season of the popular podcast series, "BIOLASE: Advancing Dentistry." Due to the overwhelmingly positive response from the dental community, the rising interest and popular demand, the second season will maintain the high level of excellence associated with the BIOLASE podcast. Season 2 will continue to provide world-class education in a readily accessible and visually appealing format focusing on trending topics for dental clinicians, including how the Company's Waterlase technology can improve patient and practice outcomes. The podcast will continue to be available on Spotify and Apple podcast platforms. Dr. Stephen John, DDS, a periodontist with over 17 years of Waterlase experience, will return to host season 2. Dr. John's extensive experience and connections within the dental community have allowed BIOLASE access to the top echelon of practitioners in the industry, and listeners will continue to be able to tune into these conversations in season 2 of the podcast. "The BIOLASE Advancing Dentistry podcast has been a rewarding, entertaining, and value-added resource for our BIOLASE education community," commented John Beaver, President and Chief Executive Officer of BIOLASE. "We are committed to raising the awareness of our Waterlase technology, and this focused educational offering exemplifies our industry leadership and commitment to educating patients and clinicians and making laser dentistry the gold standard of care." Past episodes have included a three-part peri-implantitis management series with key opinion leaders (KOLs), including Dr. Samuel Low's two-part discussion with Dr. Howard Golan, which focused on restorative and soft tissue surgeries for the general dentist using Waterlase. Additionally, season 1 also included a three-part exploration of the game-changing implementation of Epic diode lasers for the hygiene practice with Lynn Atkinson, a pioneering hygiene educator. Other guests have included Dr. Ben Curtis, who focused on Waterlase benefits to pediatrics, Dr. Scott Thompson's discussion on BIOALSE's unique Waterlase Exclusive Trial Program, and additional podcasts with Dr. Low, which centered on the release of new minimally-invasive esthetic protocols. Season 2 episodes will feature Dr. Stephen John and distinguished guests, including notable peri-implantitis expert Dr. Paul Chang, a dual board certified periodontist and prosthodontist; laser integration and return on investment (ROI) expert Dr. Russell Morrow; the former Regional Doctor Mentor of Operations for Heartland Dental DSO, Dr. Rishita Jaju, a Harvard-trained pediatric dentist with an Advanced Laser Proficiency certification; and other guests discussing trending topics, including holistic dentistry. All episodes are available at the following links: Spotify, Apple and BIOLASE Podcasts. About BIOLASE BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2021, BIOLASE has sold over 43,300 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications. For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at , Facebook at , Twitter at , Instagram at , and LinkedIn at . BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc. Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, regarding BIOLASE's expected revenue and revenue growth and beliefs regarding its financial resources. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's most recent annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements. For further information, please contact: EVC Group LLC Michael Polyviou / Todd Kehrli (732) 933-2754 mpolyviou@evcgroup.com / tkehrli@evcgroup.com View original content to download multimedia: SOURCE BIOLASE, Inc. Company Codes: NASDAQ-SMALL:BIOL